What does this research mean for the field?

Atorvastatin attenuates amikacin-induced ototoxicity and hearing loss in rats, likely through its antioxidant and anti-inflammatory properties. Novelty: ClaimNovelty.INCREMENTAL. Consensus alignment: ConsensusAlignment.NEUTRAL.

What question did this study set out to answer?

To evaluate the protective efficacy of atorvastatin against amikacin-induced ototoxicity and permanent hearing impairment in a rat model.

September 2, 2026Medical Journal of Western Black SeaOpen Access

Atorvastatin's protective effect against amikacin-induced ototoxicity: An experimental study in rats

View Full Paper

Ask AI

Bookmark

Authors

MKMüyeser Burcu Saygılı Kaya DBDeniz Baklacı ŞÇŞeyda Akbal Çufalı

Discussion

Member takes

Overview

Experimental study demonstrates that atorvastatin reduces amikacin-induced hearing loss in rats, suggesting a potential strategy to prevent aminoglycoside ototoxicity.

Key Points

To evaluate the protective efficacy of atorvastatin against amikacin-induced ototoxicity and permanent hearing impairment in a rat model.
Assigned 20 Wistar Albino rats to four treatment arms: control, atorvastatin alone (10 mg/kg/day), amikacin alone (600 mg/kg/day), and amikacin combined with atorvastatin.
Assessed auditory function on days 0, 7, and 14 using Auditory Brainstem Response (ABR) thresholds and Distortion Product Otoacoustic Emission (DPOAE) measurements across high frequencies (4000–6000 Hz).
Amikacin monotherapy led to significant hearing loss on days 7 and 14 relative to baseline (p < 0.001).
Concurrent atorvastatin treatment preserved significantly better auditory thresholds compared with amikacin alone (p < 0.001).
DPOAE amplitudes declined significantly at 4000–6000 Hz in both amikacin cohorts on days 7 and 14 (p < 0.001), but this reduction was markedly less pronounced in the atorvastatin combination arm.

Cite This Study

Kaya et al. (2026) studied this question.

synapsesocial.com/papers/6a97e25ec562ede874ec675e https://doi.org/10.29058/mjwbs.1879140

View Full Paper

Ask AI

Bookmark

September 2, 2026Medical Journal of Western Black SeaOpen Access

Atorvastatin's protective effect against amikacin-induced ototoxicity: An experimental study in rats

View Full Paper

Ask AI

Bookmark

Authors

MKMüyeser Burcu Saygılı Kaya DBDeniz Baklacı ŞÇŞeyda Akbal Çufalı

Discussion

Member takes

Overview

Experimental study demonstrates that atorvastatin reduces amikacin-induced hearing loss in rats, suggesting a potential strategy to prevent aminoglycoside ototoxicity.

Key Points

To evaluate the protective efficacy of atorvastatin against amikacin-induced ototoxicity and permanent hearing impairment in a rat model.
Assigned 20 Wistar Albino rats to four treatment arms: control, atorvastatin alone (10 mg/kg/day), amikacin alone (600 mg/kg/day), and amikacin combined with atorvastatin.
Assessed auditory function on days 0, 7, and 14 using Auditory Brainstem Response (ABR) thresholds and Distortion Product Otoacoustic Emission (DPOAE) measurements across high frequencies (4000–6000 Hz).
Amikacin monotherapy led to significant hearing loss on days 7 and 14 relative to baseline (p < 0.001).
Concurrent atorvastatin treatment preserved significantly better auditory thresholds compared with amikacin alone (p < 0.001).
DPOAE amplitudes declined significantly at 4000–6000 Hz in both amikacin cohorts on days 7 and 14 (p < 0.001), but this reduction was markedly less pronounced in the atorvastatin combination arm.

Cite This Study

Kaya et al. (2026) studied this question.

synapsesocial.com/papers/6a97e25ec562ede874ec675e https://doi.org/10.29058/mjwbs.1879140

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

View Full Paper

Ask AI

Bookmark